Photosensitive compounds found in herbs have been reported in recent years as having a variety of interesting medicinal and biological activities. In this review, we focus on photosensitizers such as hypericin and its model compounds emodin, quinizarin, and danthron, which have antiviral, antifungal, antineoplastic, and antitumor effects. They can be utilized as potential agents in photodynamic therapy, especially in photodynamic therapy (PDT) for cancer. We aimed to give a comprehensive summary of the physical and chemical properties of these interesting molecules, emphasizing their mechanism of action in relation to their different interactions with biomacromolecules, specifically with DNA.

Department of Chemistry Biochemistry and Biophysics University of Veterinary Medicine and Pharmacy Komenského 73 041 81 Košice Slovakia

Institute of Biophysics and Informatics 1st Faculty of Medicine Charles University Kateřinská 1 121 08 Prague Czech Republic

Zobrazit více v PubMed

Castano A.P., Demidova T.N., Hamblin M.R. Mechanisms in photodynamic therapy: Part one—photosensitizers, photochemistry and cellular localization. Photodiagnosis. Photodyn. Ther. 2004;1:279–293. doi: 10.1016/S1572-1000(05)00007-4. PubMed DOI PMC

Deda D.K., Araki K. Nanotechnology, light and chemical action: An effective combination to kill cancer cells. J. Braz. Chem. Soc. 2015;26:2448–2470. doi: 10.5935/0103-5053.20150316. DOI

Allen T.M., Hansen C.B., Demenzes D.E.L. Pharmacokinetics of long circulating liposomes. Adv. Drug Deliv. Rev. 1995;16:267–284. doi: 10.1016/0169-409X(95)00029-7. DOI

Loomis K., McNeeley K., Bellamkonda R.V. Nanoparticles with targeting triggered release and imaging functionality for cancer application. Soft. Matter. 2011;7:839–856. doi: 10.1039/C0SM00534G. DOI

Reddi E. Role of delivery vehicles for photosensitizers in the photodynamic therapy of tumors. J. Photochem. Photobiol. B. 1997;37:189–195. doi: 10.1016/S1011-1344(96)07404-0. PubMed DOI

Huntošová V., Buzová D., Petrovajová D., Kasak P., Naďová Z., Jancura D., Sureau F., Miškovský P. Development of a new LDL-based transport system for hydrophobic/amphiphilic drug delivery to cancer cells. Int. J. Pharm. 2012;436:463–471. doi: 10.1016/j.ijpharm.2012.07.005. PubMed DOI

Hally C., Delcanale P., Nonell S., Viappiani C., Abbruzzetti S. Photosensitizing proteins for antibacterial photodynamic inactivation. Transl. Biophotonics. 2020:e201900031. doi: 10.1002/tbio.201900031. DOI

Ghorbani J., Rahban D., Aghamiri S., Teymouri A., Bahador A. Photosensitizers in antibacterial photodynamic therapy: An overview. Laser Ther. 2018;27:293–302. doi: 10.5978/islsm.27_18-RA-01. PubMed DOI PMC

Buriankova L., Buzova D., Chorvat D., Sureau F., Brault D., Miskovsky P., Jancura D. Kinetics of hypericin association with low-density lipoproteins. Photochem. Photobiol. 2011;87:56–63. doi: 10.1111/j.1751-1097.2010.00847.x. PubMed DOI

Lenkavska L., Blascakova L., Jurasekova Z., Macajova M., Bilcik B., Cavarga I., Miskovsky P., Huntosova V. Benefits of hypericin transport and delivery by low- and high-density lipoproteins to cancer cells: From in vitro to ex ovo. Photodiagnosis Photodyn. Ther. 2019;25:214–224. doi: 10.1016/j.pdpdt.2018.12.013. PubMed DOI

Konan Y.N., Gurny R., Allemann E. State of the art in the delivery of photosensitizers for photodynamic therapy. J. Photochem. Photobiol. B Biol. 2002;66:89–106. doi: 10.1016/S1011-1344(01)00267-6. PubMed DOI

Firestone R.A. Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjugate Chem. 1994;5:105–113. doi: 10.1021/bc00026a002. PubMed DOI

Versluis A.J., van Geel P.J., Oppellar H., van Berkel T.J., Bijsterbosch M.K. Receptor-mediated uptake of low-density lipoprotein by B16 melanoma cells in vitro and in vivo in mice. Br. J. Cancer. 1996;4:525–532. doi: 10.1038/bjc.1996.396. PubMed DOI PMC

Rensen P.C., de Vrueh R.L., Kuiper J., Bijsterbosch M.K., Biessen E.A., van Berkel T.J. Recombinant lipoproteins: Lipoprotein-like lipid particles for drug targeting. Adv. Drug Deliv. Rev. 2001;47:251–276. doi: 10.1016/S0169-409X(01)00109-0. PubMed DOI

Kader A., Pater. A. Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells. J. Control. Release. 2002;80:29–44. doi: 10.1016/S0168-3659(01)00536-3. PubMed DOI

Zheng G., Chen J., Li H., Glickson J.D. Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc. Natl. Acad. Sci. USA. 2005;102:17757–17762. doi: 10.1073/pnas.0508677102. PubMed DOI PMC

Song L., Li H., Sunar U., Chen J., Corbin I., Yodh A.G., Zheng G. Naphthalocyanine-reconstituted LDL nanoparticles for in vivo cancer imaging and treatment. Int. J. Nanomed. 2007;2:767–774. PubMed PMC

Dougherty T.J., Gomer C.J., Henderson B.W., Jori G., Kessel D., Korbelik M., Moan J., Peng Q. Photodynamic therapy. J. Natl. Cancer Inst. 1998;90:889–905. doi: 10.1093/jnci/90.12.889. PubMed DOI PMC

Wilson B.C., Patterson M.S. The physics, biophysics and technology of photodynamic therapy. Phys. Med. Biol. 2008;53:R61–R109. doi: 10.1088/0031-9155/53/9/R01. PubMed DOI

Yano S., Hirohara S., Obata M., Hagiya Y., Ogura S., Ikeda A., Kataoka H., Tanaka M., Joh T. Current states and future views in photodynamic therapy. J. Photochem. Photobiol. C Photochem. Rev. 2011;12:46–67. doi: 10.1016/j.jphotochemrev.2011.06.001. DOI

Lim C.K., Heo J., Shin S., Jeong K., Seo Y.H., Jang W.D., Park C.R., Park S.Y., Kim S., Kwon I.C. Nanophotosensitizers toward advanced photodynamic therapy of cancer. Cancer Lett. 2013;334:176–187. doi: 10.1016/j.canlet.2012.09.012. PubMed DOI

Bechet D., Mordon S.R., Guillemin F., Barberi-Heyob M.A. Photodynamic therapy of malignant brain tumours: A complementary approach to conventional therapies. Cancer Treat. Rev. 2014;40:229–241. doi: 10.1016/j.ctrv.2012.07.004. PubMed DOI

Benov L. Photodynamic therapy: Current status and future direction. Med. Princ. Pract. 2015;24:14–28. doi: 10.1159/000362416. PubMed DOI PMC

Miguel-Gomez L., Vano-Galvan S., Perez-Garcia B., Carrillo-Gijon R., Jaen-Olasolo P. Treatment of folliculitis decalvans with photodynamic therapy: Results in 10 patients. J. Am. Acad. Dermatol. 2015;72:1085–1087. doi: 10.1016/j.jaad.2015.02.1120. PubMed DOI

Sharman W.M., Allen C.M., van Lier J.E. Photodynamic therapeutics: Basic principles and clinical applications. Drug Discov. Today. 1999;4:507–517. doi: 10.1016/S1359-6446(99)01412-9. PubMed DOI

Jin Y., Zhang X., Kang H., Du L., Li M. Nanostructures of an amphiphilic zinc phthalocyanine polymer conjugate for photodynamic therapy of psoriasis. Colloids Surf. B. 2015;128:405–409. doi: 10.1016/j.colsurfb.2015.02.038. PubMed DOI

Sharman W.M., van Lier J.E., Allen C.M. Targeted photodynamic theory via receptor mediated delivery systems. Adv. Drug Deliv. Rev. 2004;56:53–76. doi: 10.1016/j.addr.2003.08.015. PubMed DOI

Cruess A.F., Zlateva G., Pleil A.M., Wirostko B. Photodynamic therapy with verteporfin in age-related macular degeneration: A systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties. Acta Ophthalmol. 2009;87:118–132. doi: 10.1111/j.1755-3768.2008.01218.x. PubMed DOI

Rockson S.G., Lorenz D.P., Cheong W.F., Woodburn K.W. Photoangioplasty: An emerging clinical cardiovascular role for photodynamic therapy. Circulation. 2000;102:591–596. doi: 10.1161/01.CIR.102.5.591. PubMed DOI

Bozzini G., Colin P., Betrouni N., Nevoux P., Ouzzane A., Puech P., Willers A., Mordon S. Photodynamic therapy in urology: What can we do now and where are we heading. Photodiagn. Photodyn. Ther. 2012;9:261–273. doi: 10.1016/j.pdpdt.2012.01.005. PubMed DOI

Panzarini E., Inguscio V., Dini L. Immunogenic cell death: Can it be exploited in photodynamic therapy for cancer. Biomed. Res. Int. 2013;2013:482160. doi: 10.1155/2013/482160. PubMed DOI PMC

Lang G.E., Mennel S., Spital G., Wachtlin J., Jurklies B., Heimann H., Damato B., Meyer C.H. Different indications of photodynamic therapy in ophthalmology. Klin. Monbl. Augenheilkd. 2009;226:725–739. doi: 10.1055/s-0028-1109514. PubMed DOI

Trindade A.C., De Figueiredo J.A.P., Steier L., Weber J.B.B. Photodynamic therapy in endodontics: A literature review. Photomed. Laser Surg. 2015;33:175–182. doi: 10.1089/pho.2014.3776. PubMed DOI

Vohra F., Al-Kheraif A.A., Qadri T., Hassan M.I.A., Ahmedef A., Warnakulasuriya S., Javed F. Efficacy of photodynamic therapy in the management of oral premalignant lesions. A systematic review. Photodiagn. Photodyn. Ther. 2015;12:150–159. doi: 10.1016/j.pdpdt.2014.10.001. PubMed DOI

Karrer S., Kohl E., Feise K., Hiepe-Wegener D., Lischner S., Philipp-Dormston W., Podda M., Prager W., Walker T., Szeimies R.M. Photodynamic therapy for skin rejuvenation: Review and summary of the literature-results of a consensus conference of an expert group for aesthetic photodynamic therapy. J. Dtsch. Dermatol. Ges. 2013;11:137–148. doi: 10.1111/j.1610-0387.2012.08046.x. PubMed DOI

Fuhrmann G., Serio A., Mazo M., Nair R., Stevens M.M. Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins. J. Control. Release. 2015;205:35–44. doi: 10.1016/j.jconrel.2014.11.029. PubMed DOI

Baptista M.S., Wainwright M. Photodynamic antimicrobial chemotherapy (PACT) for the treatment of malaria, leishmaniasis and trypanosomiasis. Braz. J. Med. Res. 2011;44:1–10. doi: 10.1590/S0100-879X2010007500141. PubMed DOI

Goslinski T., Piskorz J. Fluorinated porphyrinoids and their biomedical applications. J. Photochem. Photobiol. C Photochem. Rev. 2011;12:304–321. doi: 10.1016/j.jphotochemrev.2011.09.005. DOI

Hanakova A., Bogdanova K., Tomankova K., Pizova K., Malohlava J., Binder S., Bajgar R., Langova K., Kolar M., Mosinger J., et al. The application of antimicrobial photodynamic therapy on S. aureus and E. coli using porphyrin photosensitizers bound to cyclodextrin. Microbiol. Res. 2014;169:163–170. doi: 10.1016/j.micres.2013.07.005. PubMed DOI

Baltazar L.M., Ray A., Santos D.A., Cisalpino P.S., Friedman A.J., Nosanchuk J.D. Antimicrobial photodynamic therapy: An effective alternative approach to control fungal injections. Front. Microbiol. 2015;6:202. doi: 10.3389/fmicb.2015.00202. PubMed DOI PMC

Bonnett R. Progress with heterocyclic photosensitizers for the photodynamic therapy (PDT) of tomours. J. Heterocyclic Chem. 2002;39:455. doi: 10.1002/jhet.5570390303. DOI

Photolitec, LLC Tumor Specific Imaging Therapy. [(accessed on 10 August 2020)];Photodynamic Therapy. Available online: http://photolitec.org/Tech_PDT.html.

Vatansever F., de Melo W.C.M.A., Avci P., Vecchio D., Sadasivam M., Gupta A., Chandran R., Karimi M., Parizotto N.A., Yin R., et al. Antimicrobial strategies centered around reactive oxygen species—bactericidal antibiotics, photodynamic therapy, and beyond. Microbiol. Rev. 2013;37:955–989. doi: 10.1111/1574-6976.12026. PubMed DOI PMC

Henderson B.W., Dougherty T.J. How does photodynamic therapy work. Photochem. Photobiol. 1992;55:145–157. doi: 10.1111/j.1751-1097.1992.tb04222.x. PubMed DOI

Agostinis P., Berg K., Cengel K.A., Foster T.H., Girotti A.W., Gollnick S.O., Hahn S.M., Hamblin M.R., Juzeniene A., Kessel D., et al. Photodynamic therapy of cancer: An update. CA Cancer J. Clin. 2011;61:250–281. doi: 10.3322/caac.20114. PubMed DOI PMC

Senapathy G.J., George B.P., Abrahamse H. Exloring the role of phytochemicals as potent natural photosensitizers in photodynamic therapy. Anticancer Agents Med. Chem. 2020;20:1831–1844. doi: 10.2174/1871520620666200703192127. PubMed DOI

Moan J., Berg K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem. Photobiol. 1991;53:549–553. doi: 10.1111/j.1751-1097.1991.tb03669.x. PubMed DOI

Hatz S., Poulsen L., Ogilby P.R. Time-resolved singlet oxygen phosphorescence measurements from photosensitized experiments in single cells: Effects of oxygen diffusion and oxygen concentration. Photochem. Photobiol. 2008;84:1284–1290. doi: 10.1111/j.1751-1097.2008.00359.x. PubMed DOI

Nyst H.J., Tan I.B., Stewart F.A., Balm A.J.M. Is photodynamic therapy a good alternative to surgery and radiotherapy in the treatment of head and neck cancer. Photodiagnosis Photodyn. Ther. 2009;6:3–11. doi: 10.1016/j.pdpdt.2009.03.002. PubMed DOI

Schafer M. High sensitivity of Deinococcus radiodurans to photodynamically-produced singlet oxygen. Int. J. Radiat. Biol. 1998;74:249–253. doi: 10.1080/095530098141636. PubMed DOI

Kochevar I.E., Lambert C.R., Lynch M.C., Tedesco A.C. Comparison of photosensitized plasma membrane damage caused by singlet oxygen and free radicals. Biochim. Biophys. Acta. 1996;1280:223–230. doi: 10.1016/0005-2736(95)00297-9. PubMed DOI

Barr H., Tralau C.J., Boulos P.B., MacRobert A.J., Tilly R., Bown S.G. The contrasting mechanisms of colonic collagen damage between photodynamic therapy and thermal injury. Photochem. Photobiol. 1987;46:795–800. doi: 10.1111/j.1751-1097.1987.tb04850.x. PubMed DOI

Hopper C. Photodynamic therapy. A clinical reality in the treatment of cancer. Lancet. Oncol. 2000;1:212–219. doi: 10.1016/S1470-2045(00)00166-2. PubMed DOI

Allison R.R., Bagnato V.S., Sibata C.H. Future of oncologic photodynamic therapy. Future Oncol. 2010;6:929–940. doi: 10.2217/fon.10.51. PubMed DOI

Foote C. Mechanisms of photo-oxygenation. In: Doiron D.R., Gomer C.J., editors. Porphyrin Localization and Treatment of Tumors. 1st ed. Alan R. Liss; New York, NY, USA: 1984. pp. 3–18.

Boegheim J.P., Scholte H., Dubbehman T.M., Beems E., Raap A.K., van Steveninck J. Photodynamic effects of hematoporphyrin-derivative on enzyme activities of murine L929 fibroblasts. J. Photochem. Photobiol. B. 1987;1:61–73. doi: 10.1016/1011-1344(87)80006-4. PubMed DOI

Gibson S.L., Hilf R. Interdependence of fluence, drug, dose and oxygen on hematoporphyrin derivate induced photosensitization of tumor mitochondria. Photochem. Photobiol. 1985;42:367–373. doi: 10.1111/j.1751-1097.1985.tb01583.x. PubMed DOI

Dolmans D.E., Fukumura D., Jain R.K. Photodynamic therapy for cancer. Nat. Rev. Cancer. 2003;3:380–387. doi: 10.1038/nrc1071. PubMed DOI

Ochsner M. Photophysical and photobiological processes in the photodynamic therapy of tumors. J. Photochem. Photobiol. B. 1997;39:1–18. doi: 10.1016/S1011-1344(96)07428-3. PubMed DOI

Canti G., Lattuada D., Morelli S., Nicolin A., Cubeddu R., Taroni P., Valentini G. Efficacy of photodynamic therapy against doxorubicin-resistant murine tumors. Cancer Lett. 1995;93:255–259. doi: 10.1016/0304-3835(95)03818-H. PubMed DOI

Lofgren L.A., Hallgren S., Nilsson E., Westerborn A., Nilsson C., Reizenstein J. photodynamic therapy for recurrent nasopharyngeal cancer. Arch. Otolaryngol. Head Neck Surg. 1995;121:997–1002. doi: 10.1001/archotol.1995.01890090039008. PubMed DOI

Davies M.J. Singlet oxygen-mediated damage to proteins and its consequences. Biochem. Biophys. Res. Commun. 2003;305:761–770. doi: 10.1016/S0006-291X(03)00817-9. PubMed DOI

Bicalho L.S., Longo J.P.F., Pereira L.O., Santos M.F.M.A., Azevedo R.B. Photodynamic therapy, a new approach in the treatment of oral cancer. Rev. Univ. Ind. Santander. Salud. 2010;42:167–174.

Yoo J.O., Lim Y.C., Kim Y.M., Ha K.S. Differential cytotoxic responses to low-and high-dose photodynamic therapy in human gastric and bladder cancer cells. J. Cell Biochem. 2011;112:3061–3071. doi: 10.1002/jcb.23231. PubMed DOI

Moghissi K., Dixon K., Parson R.J. A controlled trial of Nd-YAG laser vs photodynamic therapy for odvanced malignant bronchial obstruction. Laser Med. Sci. 1993;8:269–273. doi: 10.1007/BF02547850. DOI

Kato H., Okunaka T., Shimatani H. Photodynamic therapy for early state bronchogenic carcinoma. J. Clin. Laser Med. Surg. 1996;14:235–238. doi: 10.1089/clm.1996.14.235. PubMed DOI

Manoto S.L., Abrahamse H. Effect of a newly synthesized Zn sulfophthalocyanine derivative on cell morphology, viability, proliferation, and cytotoxicity in a human lung cancer cell line (A549) Lasers Med. Sci. 2011;26:523–530. doi: 10.1007/s10103-011-0887-0. PubMed DOI

Jheon S., Lee J.M., Kim J.K., Kim K.H., Seo S.J. Photodynamic therapy for tracheobronchial cancer. Photodiagnosis Photodyn. Ther. 2011;6:177. doi: 10.1016/j.pdpdt.2011.03.176. DOI

Grant W.E., MacRobert A.J., Bown S.G., Hopper C., Speight P.M. Photodynamic therapy of oral cancer: Photosensitization with systemic aminolaevulinic acid. Lancet. 1993;342:147–148. doi: 10.1016/0140-6736(93)91347-O. PubMed DOI

Barr H., Shepherd N.A., Dix A., Roberts D.J.H., Tan W.C., Krasner N. Eradication of high-grade dysplasia in columnar-lined (Barrett´s) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet. 1996;348:584–585. doi: 10.1016/S0140-6736(96)03054-1. PubMed DOI

Miller J.D., Baron E.D., Scull H., Hsia A., Berlin J.C., McCormick T., Colussi V., Kenney M.E., Cooper K.D., Oleinick N.L. Photodynamic therapy with the phtalocyanin photosensitizer Pc 4: The case experience with preclinical mechanistic and early clinical-tranlational studies. Toxicol. Appl. Pharmacol. 2007;224:290–299. doi: 10.1016/j.taap.2007.01.025. PubMed DOI PMC

Nseyo U.O., DeHaven J., Dougherty T.J., Potter W.R., Merrill D.L., Lundahl S.L., Lamm D.L. Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: A long-term experience. J. Clin. Laser Med. Surg. 1998;16:61–68. doi: 10.1089/clm.1998.16.61. PubMed DOI

Leon S.P., Folkerth R.D., Black P. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer. 1996;77:362–372. doi: 10.1002/(SICI)1097-0142(19960115)77:2<362::AID-CNCR20>3.0.CO;2-Z. PubMed DOI

Zhu T.C., Finlay J.C. The role of photodynamic therapy (PDT) physics. Med. Phys. 2008;35:3127–3136. doi: 10.1118/1.2937440. PubMed DOI PMC

George B.P.A., Abrahamse H. A review on novel breast cancer therapies: Photodynamic therapy and plant derived agent induced cell death mechanisms. Anticancer Agents Med. Chem. 2016;16:793–801. doi: 10.2174/1871520615666151026094028. PubMed DOI

Kostović K., Pastar Z., Ceović R., Mokos Z.B., Buzina D.S., Stanimirović A. Photodynamic therapy in dermatology: Current treatments and implications. Coll. Antropol. 2012;36:1477–1481. PubMed

Kessel D. Photosensitization of viral particles. J. Lab. Clin. Med. 1990;116:428. PubMed

Tardivo J.P., Del Giglio A., Paschoal L.H., Baptista M.S. New photodynamic therapy protocol to treat AIDS-related Kaposi´s sarcoma. Photomed. Laser Surg. 2006;24:528–531. doi: 10.1089/pho.2006.24.528. PubMed DOI

Mĺkvy P. Position and possibilities of photodynamic therapy in oncology. Oncology. 2007;5:299–301.

Castano A.P., Demidova T.N., Hamblin M.R. Mechanisms in photodynamic therapy: Part three—Photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction. Photodiagnosis Photodyn. Ther. 2005;2:91–106. doi: 10.1016/S1572-1000(05)00060-8. PubMed DOI PMC

Muniyandi K., George B., Parimelazhagan T., Abrahamse H. Role of photoactive phytocompounds in photodynamic therapy of cancer. Molecules. 2020;25:4102. doi: 10.3390/molecules25184102. PubMed DOI PMC

Doherty R.E., Sazanovich I.V., McKenzie L.K., Stasheuski A.S., Coyle R., Baggaley E., Bottomley S., Weinstein J.A., Bryant H.E. Photodynamic killing of cancer cells by a platinum(II) complex with cyclometallating ligand. Sci. Rep. 2016;6:22668. doi: 10.1038/srep22668. PubMed DOI PMC

Pouton C.W., Wagstaff K.M., Roth D.M., Moseley G.W., Jans D.A. Targeted delivery to the nucleus. Adv. Drug Deliv. Rev. 2007;59:698–717. doi: 10.1016/j.addr.2007.06.010. PubMed DOI

Sobolev A.S. Novel modular transporters delivering anticancer drugs and foreign DNA to the nuclei of target cancer cells. J. Buon. 2009;14(Suppl. 1):S33–S42. PubMed PMC

de Melo W.C.M.A., Lee A.N., Perussi J.R., Hamblin M.R. Electroporation enhances antimicrobial photodynamic therapy mediated by the hydrophobic photosensitizer, hypericin. Photodiagnosis Photodyn. Ther. 2013;10:647–650. doi: 10.1016/j.pdpdt.2013.08.001. PubMed DOI PMC

Alves D.S., Pérez-Fons L., Estepa A., Micol V. Membrane-related effects underlying the biological activity of the anthraquinones emodin and barbaloin. Biochem. Pharmacol. 2004;68:549–561. doi: 10.1016/j.bcp.2004.04.012. PubMed DOI

Du K., Xia Q., Heng H., Feng F. Temozolomide-doxorubicin conjugate as a double intercalating agent and delivery by apoferritin for glioblastoma chemotherapy. ACS Mater. Interfaces. 2020;12:34599–34609. doi: 10.1021/acsami.0c08531. PubMed DOI

Mandelli F., Vignetti M., Suciu S., Stasi R., Petti M.C., Meloni G., Muus P., Marmont F., Marie J.P., Labar B., et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: The EORTC and GIMEMA groups study AML-10. J. Clin. Oncol. 2009;27:5397–5403. doi: 10.1200/JCO.2008.20.6490. PubMed DOI PMC

Wójcik K., Zarebski M., Cossarizza A., Dobrucki J.W. Daunomycin, an antitumor DNA intercalator, influences histone-DNA interactions. Cancer Biol. Ther. 2013;14:823–832. doi: 10.4161/cbt.25328. PubMed DOI PMC

Hu X., Cao Y., Yin X., Zhu L., Chen Y., Wang W., Hu J. Design and synthesis of various quinizarin derivatives as potential anticancer agents in acute T lymphoblastic leukemia. Bioorganic Med. Chem. 2019;27:1362–1369. doi: 10.1016/j.bmc.2019.02.041. PubMed DOI

Chen H., Zhao C., He R., Zhou M., Liu Y., Guo X., Wang M., Zhu F., Qin R., Li X. Danthron suppresses autophagy and sensitizers pancreatic cancer cells to doxorubicin. Toxicol. In Vitro. 2019;54:345–353. doi: 10.1016/j.tiv.2018.10.019. PubMed DOI

Wang Y., Yang M., Qian J., Xu W., Wang J., Hou G., Ji L., Suo A. Sequentially self-assembled polysaccharide-based nanocomplexes for combined chemotherapy and photodynamic therapy of breast cancer. Carbohydr. Polym. 2019;203:203–213. doi: 10.1016/j.carbpol.2018.09.035. PubMed DOI

Lee H., Han J., Shin H., Han H., Na K., Kim H. Combination of chemotherapy and photodynamic therapy for cancer treatment with sonoporation effects. J. Control. Release. 2018;283:190–199. doi: 10.1016/j.jconrel.2018.06.008. PubMed DOI

He C., Liu D., Lin W. self-assembled core-shell nanoparticles for combined chemotherapy and photodynamic therapy of resistant head and neck cancers. ACS Nano. 2015;9:991–1003. doi: 10.1021/nn506963h. PubMed DOI

Gleason H.A., Cronquist A. Manual of Vascular Plants of Northeastern United States and Adjacent Canada. 2nd ed. New York Botanical Garden; Bronx, New York, NY, USA: 1991. p. 910.

Rahman A. Bioactive natural products (Part C) In: Rahman A., editor. Studies in Natural Products Chemistry. 1st ed. Volume 22. Elsevier; Amsterdam, The Netherlands: 2000. p. 647.

Miškovský P. Hypericin—A new antiviral and antitumor photosensitizer: Mechanism of action and interaction with biological macromolecules. Curr. Drug Targets. 2002;3:55–84. doi: 10.2174/1389450023348091. PubMed DOI

Thornett A. Use of hypericin as antidepressant. Valid measure of antidepressant efficacy in primary care is needed. Brit. Med. J. 2000;320:1141. PubMed PMC

Butterweck V., Winterhoff H., Herkenham M. St John´s wort, hypericin, and imipramine: A comparative analysis of mRNA levels in brain areas involved in HPA axis control following short-term and long-term administration in normal and stressed rats. Mol. Psychiatry. 2001;6:547–564. doi: 10.1038/sj.mp.4000937. PubMed DOI

Eberman R., Alth G., Kreitner M., Kubin A. Natural products derived from plants as potential drugs for the photodynamic destruction of tumor cells. J. Photochem. Photobiol. B. 1996;36:95–97. doi: 10.1016/S1011-1344(96)07353-8. PubMed DOI

Pengelly A. The Constituents of Medical Plants: An Introduction to the Chemistry and Therapeutics of Herbal Medicine. 2nd ed. CABI Publishing; Cambridge, UK: 2004. pp. 20–50.

Miroššay A., Mirossay L., Tóthová J., Miškovský P., Onderková H., Mojžiš J. Potentiation of hypericin and hypocrellin-induced phototoxicity by omeprazole. Phytomedicine. 1999;6:311–317. doi: 10.1016/S0944-7113(99)80051-8. PubMed DOI

Cavarga I., Brezani P., Fedorocko P., Miskovsky P., Bobrov N., Longauer F., Rybarova S., Mirossay L., Stubna J. Photoinduced antitumor effect of hypericin can be enhanced by fractionated dosing. Photomedicine. 2005;12:680–683. doi: 10.1016/j.phymed.2004.02.011. PubMed DOI

Plenagl N., Duse L., Seitz B.S., Goergen N., Pinnapireddy S.R., Jedelska J., Brűβler J., Bakowsky U. Photodynamic therapy—hypericin tetraether liposome conjugates and their antitumor and antiangiogenic activity. J. Drug Deliv. 2019;26:23–33. doi: 10.1080/10717544.2018.1531954. PubMed DOI PMC

Bianchini P., Cozzolino M., Oneto M., Pesce L., Pennacchietti F., Tognolini M., Giorgio C., Nonell S., Cavanna L., Delcanale P., et al. Hypericin-apomyoglobin an enhanced photosensitizer complex for the treatment of tumor cells. Biomacromolecules. 2019;20:2024–2033. doi: 10.1021/acs.biomac.9b00222. PubMed DOI

Fiebich B.L., Lieb A.H. Inhibition of substance P induced cytokine synthesis by St John´s Wort extracts. Pharmacopsychiatry. 2001;34:526–528. doi: 10.1055/s-2001-15462. PubMed DOI

Samadi S., Khadivzadeh T., Emami A., Moosavi N.S., Tafaghodi M., Behnam H.R. The effect of Hypericum perforatum on the wound healing and scar of cesarean. J. Altern. Complement. Med. 2010;16:113–117. doi: 10.1089/acm.2009.0317. PubMed DOI

Hajhashemi M., Ghanbari Z., Movahedi M., Rafieian M., Keivani A., Haghollahi F. The effect of Achillea millefolium and Hypericum perforatum ointments on episiotomy wound healing in primiparous women. J. Matern. Fetal Neonatal Med. 2018;31:63–69. doi: 10.1080/14767058.2016.1275549. PubMed DOI

García I., Ballesta S., Gilaberte Y., Rezusta A., Pascual Á. Antimicrobial photodynamic activity of hypericin against methicillin-susceptible and resistant Staphylococcus aureus biofilms. Future Microbiol. 2015;10:347–356. doi: 10.2217/fmb.14.114. PubMed DOI

Engelhardt V., Krammer B., Plaetzer K. Antibacterial photodynamic therapy using water-soluble formulations of hypericin or mTHPC is effective in inactivation of Staphylococcus aureus. Photochem. Photobiol. Sci. 2010;9:365–369. doi: 10.1039/b9pp00144a. PubMed DOI

Yow C., Tang H.M., Chu E.S., Huang Z. Hypericin-mediated photodynamic antimicrobial effect on clinically isolated pathogens. Photochem. Photobiol. 2012;88:626–632. doi: 10.1111/j.1751-1097.2012.01085.x. PubMed DOI

Rodríguez-Amigo B., Delcanale P., Rotger G., Juárez-Jiménez J., Abbruzzetti S., Summer A., Agut M., Luque F.J., Nonell S., Viappiani C. The complex of hypericin with β-lactoglobulin has antimicrobial activity with perspective applications in dairy industry. J. Dairy Sci. 2015;98:89–94. doi: 10.3168/jds.2014-8691. PubMed DOI

Delcanale P., Rodríguez-Amigo B., Juárez-Jiménez J., Luque F.J., Abbruzzetti S., Agut M., Nonell S., Viappiani C. Tuning the local solvent composition at a drug carrier surface: Effect of dimethyl sulfoxide/water mixture on the photofunctional properties of hyperici-β-lactoglobulin. Mat. Chem. B. 2017;5:1633–1641. doi: 10.1039/C7TB00081B. PubMed DOI

Pezzuoli D., Cozzolino M., Montali C., Brancaleon L., Bianchini P., Zantedeschi M., Bonardi S., Viappiani C., Abbruzzetti S. Serum albumins are efficient delivery systems for the photosensitizer hypericin in photosensitization-based treatments against Staphylococcus aureus. Food Control. 2018;94:254–262. doi: 10.1016/j.foodcont.2018.07.027. DOI

Lopez-Bazzocchi I., Hudson J.B., Towers G.H. Antiviral activity of photoactive plant pigment hypericin. Photochem. Photobiol. 1991;54:95–98. doi: 10.1111/j.1751-1097.1991.tb01990.x. PubMed DOI

Hudson J.B., Lopez-Bazzocchi I., Towers G.H. Antiviral activities of hypericin. Antivir. Res. 1991;15:101–112. doi: 10.1016/0166-3542(91)90028-P. PubMed DOI

Moraleda G., Wu T.T., Jilbert A.R., Aldrich C.E., Condreay L.D., Larsen S.H., Tang J.C., Colacino J.M., Mason W.S. Inhibition of duck hepatitis B virus replication by hypericin. Antivir. Res. 1993;20:235–247. doi: 10.1016/0166-3542(93)90023-C. PubMed DOI

Guedes R.C., Eriksson L.A. Effects of halogen substitution on the photochemical properties of hypericin. J. Photochem. Photobiol. A Chem. 2006;178:41–49. doi: 10.1016/j.jphotochem.2005.06.018. DOI

Meruelo D., Lavie G., Lavie D. Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: Aromatic polycyclic diones hypericin and pseudohypericin. Proc. Natl. Acad. Sci. USA. 1988;85:5230–5234. doi: 10.1073/pnas.85.14.5230. PubMed DOI PMC

Hudson J.B., Imperial V., Haugland R.P., Diwu Z. Antiviral activities of photoactive perylenequinones. Photochem. Photobiol. 1997;65:352–354. doi: 10.1111/j.1751-1097.1997.tb08570.x. PubMed DOI

Xu Y., Lu C. Raman spectroscopy study on structure of human immunodeficiency virus (HIV) and hypericin-induced photosensitive damage of HIV. Sci. China Ser. C. 2005;48:117–132. PubMed

Gulick R.M., McAuliffe V., Holden-Wiltse J., Crumpacker C., Liebes L., Stein D.S., Meehan P., Hussey S., Forcht J., Valentine F.T. Phase I studies of hypericin, the active compound in St. John´s Wort, as an antiretroviral agent in HIV-infected adults: AIDS clinical trials group protocols 150 and 258. Ann. Intern. Med. 1999;130:510–514. doi: 10.7326/0003-4819-130-6-199903160-00015. PubMed DOI

Kerb R., Reum T., Brockmöller J., Bauer S., Roots I. No clinically relevant photosensitization after single-dose and steady state in treatment with hypericum extract in man. Eur. J. Clin. Pharmacol. 1995;49:A156.

Diwu Z. Novel therapeutic and diagnostic applications of hypocrellins and hypericins. Photochem. Photobiol. 1995;61:529–539. doi: 10.1111/j.1751-1097.1995.tb09903.x. PubMed DOI

Wynn J.L., Cotton T.M. Spectroscopic properties of hypericin in solution and at surfaces. J. Phys. Chem. 1995;99:4317–4323. doi: 10.1021/j100012a063. DOI

Yamazaki T., Ohta N., Yamazaki I., Song P.S. Excited-state properties of hypericin: Electronic spectra and fluorescence decay kinetics. J. Phys. Chem. 1993;97:7870–7875. doi: 10.1021/j100132a013. DOI

Keša P., Antalík M. Determination of pKa constants of hypericin in aqueous solution of the anti-allergic hydrotropic drug Cromolyn disodium salt. Chem. Phys. Lett. 2017;676:112–117. doi: 10.1016/j.cplett.2017.03.059. DOI

Redepenning J., Tao N. Measurement of formal potentials for hypericin in dimethylsulfoxide. Photobiol. 1993;58:532–535. doi: 10.1111/j.1751-1097.1993.tb04927.x. PubMed DOI

Thomas C., Pardini R.S. Oxygen dependence of hypericin-induced phototoxicity to EMT6 mouse mammary carcinoma cells. Photochem. Photobiol. 1992;55:831–837. doi: 10.1111/j.1751-1097.1992.tb08531.x. PubMed DOI

Ehrenberg B., Anderson J.L., Foote C.S. Kinetics and yield of singlet oxygen photosensitized by hypericin inorganic and biological media. Photochem. Photobiol. 1998;68:135–140. doi: 10.1111/j.1751-1097.1998.tb02479.x. PubMed DOI

Roslaniec M., Weitman H., Freeman D., Mazur Y., Ehrenberg B. Liposome binding constant and singlet oxygen quantum yields of hypericin, tetrahydroxyhelianthrone and their derivatives: Studies in organic solutions and in liposomes. J. Photochem. Photobiol. B Biol. 2000;57:149–158. doi: 10.1016/S1011-1344(00)00090-7. PubMed DOI

Gbur P., Dedič R., Jancura D., Miškovský P., Hala J. Time-resolved luminescence and singlet oxygen formation under illumination of hypericin in acetone. J. Lumin. 2008;128:765–767. doi: 10.1016/j.jlumin.2007.11.073. PubMed DOI

Fehr M.J., Carpenter S.L., Petrich J.W. The role of oxygen in the photoinduced antiviral activity of hypericin. Bioorg. Med. Chem. Lett. 1994;4:1339–1344. doi: 10.1016/S0960-894X(01)80357-7. DOI

Carpenter S., Fehr J.M., Kraus G.A., Petrich J.W. Chemiluminescent activation of the antiviral activity of hypericin: A molecular flashlight. Proc. Natl. Acad. Sci. USA. 1994;91:12273–12277. doi: 10.1073/pnas.91.25.12273. PubMed DOI PMC

Verebová V., Belej D., Joniová J., Jurašeková Z., Miškovský P., Kožár T., Horváth D., Staničová J., Huntošová V. Deeper insights into the drug defense of glioma cells against hydrophobic molecules. Int. J. Pharm. 2016;503:56–67. doi: 10.1016/j.ijpharm.2016.02.042. PubMed DOI

de Witte P., Agostinis P., Van Lint J., Merlevede W., Vandenheede J.R. Inhibition of epidermal growth factor receptor tyrosine kinase activity by hypericin. Biochem. Pharmacol. 1993;46:1929–1936. doi: 10.1016/0006-2952(93)90633-8. PubMed DOI

Agostinis P., Vantieghem A., Merlevede W., de Witte P. Hypericin in cancer treatment: More light on the way. Int. J. Biochem. Cell Biol. 2002;34:221–241. doi: 10.1016/S1357-2725(01)00126-1. PubMed DOI

Buytaert E., Callewaert G., Hendrickx N., Scorrano L., Hartmann D., Missiaen L., Vandenheede J.R., Heirman I., Grooten J., Agostinis P. Role of endoplasmic reticulum depletion and multidomain proapoptic BAX and BAK proteins in shaping cell death after hypericin-mediated photodynamic therapy. Faseb. J. 2006;20:756–758. doi: 10.1096/fj.05-4305fje. PubMed DOI

Ferrario A., von Tiehl K., Wong S., Luna M., Gomer C.J. Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res. 2002;62:3956–3961. PubMed

Delcanale P., Pennacchietti F., Maestrini G., Rodríguez-Amigo B., Bianchini P., Diaspro A., Iagatti A., Patrizi B., Foggi P., Agut M., et al. Subdiffraction localization of a nanostructured photosensitizer in bacterial cells. Sci. Rep. 2015;5:15564. doi: 10.1038/srep15564. PubMed DOI PMC

Miškovský P., Sureau F., Chinsky L., Turpin P.Y. Subcellular distribution of hypericin in human cancer cells. Photochem. Photobiol. 1995;62:546–549. doi: 10.1111/j.1751-1097.1995.tb02382.x. PubMed DOI

Miškovský P., Chinsky L., Wheeler G.V., Turpin P.Y. Hypericin site specific interactions within polynucleotides used as DNA model compounds. J. Biomol. Struct. Dyn. 1995;13:547–552. doi: 10.1080/07391102.1995.10508865. PubMed DOI

Sánchez-Cortés S., Miškovský P., Jancura D., Bertoluzza A. Specific interactions of antiretroviraly active drug hypericin with DNA as studied by surface-enhanced resonance Raman spectroscopy. J. Phys. Chem. 1996;100:1938–1944. doi: 10.1021/jp951980q. DOI

Das K., Smirnov A.V., Wen J., Miškovský P., Petrich J.W. Photophysics of hypericin and hypocrellin A in complex with subcellular components: Interactions with human serum albumin. Photochem. Photobiol. 1999;69:633–645. doi: 10.1111/j.1751-1097.1999.tb03339.x. PubMed DOI

Senthil V., Jones L.R., Senthil K., Grossweiner L.J. Hypericin photosensitization in aqueous model system. Photochem. Photobiol. 1994;59:40–47. doi: 10.1111/j.1751-1097.1994.tb04999.x. PubMed DOI

Mijatovic S., Maksimovic-Ivanic D., Radovic J., Milijkovic D., Kaludjerovic G.N., Sabo T.J., Trajkovic V. Aloe emodin decreases the ERK-dependent anticancer activity of cisplatin. Cell Mol. Life Sci. 2005;62:1275–1282. doi: 10.1007/s00018-005-5041-3. PubMed DOI PMC

Ma T., Qi Q.H., Yang W.X., Xu J., Dong Z.L. Contractile effects and antracellular Ca2+ signaling induced by emodin in circular smooth muscle cells of rat colon. World J. Gastroenterol. 2003;9:1804–1807. doi: 10.3748/wjg.v9.i8.1804. PubMed DOI PMC

Janeczko M., Masčyk M., Kubiński K., Golczyk H. Emodin, a natural inhibitor of protein kinase CK2, suppresses growth, hyphal development, and biofilm formation of Candida Albicans. Yeast. 2017;34:253–265. doi: 10.1002/yea.3230. PubMed DOI

Huang H.C., Lee C.R., Lee Chao P.D., Chen C.C., Chu S.H. Vasorelaxant effects of emodin, an antraquinone from a Chinese herb. Eur. J. Pharmacol. 1991;205:289–294. PubMed

Su Y.T., Chang H.L., Shyue S.K., Hsu S.L. Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway. Biochem. Pharmacol. 2005;70:229–241. doi: 10.1016/j.bcp.2005.04.026. PubMed DOI

Chukwujelwu J.C., Coombes P.H., Mulholland D.A., van Staden J. Emodin, an antibacterial anthraquinone from the roots of Cassia occidentalis. S. Afr. J. Bot. 2006;72:295–297. doi: 10.1016/j.sajb.2005.08.003. DOI

Srinivas G., Babykutty S., Sathiadevan P.P., Srinivas P. Molecular mechanism of emodin action: Transition from laxative ingredient to an antitumor agent. Med. Res. Rev. 2007;27:591–608. doi: 10.1002/med.20095. PubMed DOI

Fernand V.E., Dinh D.T., Washington S.J., Fakayode S.O., Loss J.N., van Ravenswaay R.O., Warner I.M. Determination of pharmacologically active compounds in root extracts of Cassia Alata L. by use of high performance liquid chromatography. Talanta. 2008;74:896–902. doi: 10.1016/j.talanta.2007.07.033. PubMed DOI PMC

Hennebelle T., Weniger B., Joseph H., Sahpaz S., Bailleul F. Senna alata. Fitoterapia. 2009;80:385–393. doi: 10.1016/j.fitote.2009.05.008. PubMed DOI

Andersen D.O., Weber N.D., Wood S.G., Hughes B.G., Murray B.K., North J.A. In vitro virucidal activity of selected anthraquinones and anthraquinone derivatives. Antiviral Res. 1991;16:185–196. doi: 10.1016/0166-3542(91)90024-L. PubMed DOI

Kusari S., Lamshöft M., Zühlke S., Spiteller M. An endophytic fungus from hypericum perforatum that produces hypericin. J. Nat. Prod. 2008;71:159–162. doi: 10.1021/np070669k. PubMed DOI

Karioti A., Bilia A.R. Hypericins as potential leads for new therapeutics. Int. J. Mol. Sci. 2010;11:562–594. doi: 10.3390/ijms11020562. PubMed DOI PMC

Bogdanska A., Chmurzyński L., Ossowski T., Liwo A., Jeziorek D. Protolytic equilibria of dihydroxyanthraquinones in non-aqueous solutions. Anal. Chim. Acta. 1999;402:339–343. doi: 10.1016/S0003-2670(99)00546-2. DOI

Mueller S.O., Lutz W.K., Stopper H. Factors affecting the genotoxic potency ranking of natural anthraquinones in mammalian cell culture systems. Mutat. Res. 1998;414:125–129. doi: 10.1016/S1383-5718(98)00047-3. PubMed DOI

Li J., Yang W., Hu W., Wang J., Jin Z., Wang X., Xu W. Effects of emodin on the activity of K channel in guinea pig taenia coli smooth muscle cells. Acta Pharm. Sin. 1998;33:321–325. PubMed

Ma T., Qi Q.H., Xu J., Dong Z.L., Yang W.X. Signal pathways involved in emodin-induced contraction of smooth muscle cells from rat colon. World J. Gastroenterol. 2004;10:1476–1479. doi: 10.3748/wjg.v10.i10.1476. PubMed DOI PMC

Chen D., Xiong Y., Wang L., Lv B., Lin Y. Characteristics of emodin on modulating the contractility of jejunal smooth muscle. Can. J. Physiol. Pharmacol. 2012;90:455–462. doi: 10.1139/y2012-004. PubMed DOI

Vargas F., Fraile G., Velásquez M., Correia H., Fonseca G., Marin M., Marcano E., Sánchez Y. Studies on the photostability and phototoxicity of aloe-emodin, emodin and rhein. Pharmazie. 2002;57:399–404. PubMed

Oshida K., Hirakata M., Maeda A., Miyoshi T., Miyamoto Y. Toxicological effect of emodin in mouse testicular gene expression profile. J. Appl. Toxicol. 2011;31:790–800. doi: 10.1002/jat.1637. PubMed DOI

Xu X., Toselli A., Russell L.D., Seldin D.C. Globozospermia in mice lacking the casein kinase II α´catalytic subunit. Nat. Genet. 1999;23:118–121. doi: 10.1038/12729. PubMed DOI

Escalier D., Silvius D., Xu X. Spermatogenesis of mice lacking CK2alpha´failure of germ cell survival and characteristic modifications of the spermatid nucleus. Mol. Reprod. Dev. 2003;66:190–201. doi: 10.1002/mrd.10346. PubMed DOI

Wang L., Lin L., Ye B. Electrochemical studies of the interaction of the anticancer herbal drug emodin with DNA. J. Pharm. Biomed. Anal. 2006;42:625–629. doi: 10.1016/j.jpba.2006.05.017. PubMed DOI

Bi S., Zhang H., Qiao C., Sun Y., Liu C. Studies of interaction of emodin and DNA in the presence of ethidium bromide by spectroscopic method. Spectrochim. Acta A Mol. Biomol. Spectrosc. 2008;69:123–129. doi: 10.1016/j.saa.2007.03.017. PubMed DOI

Saito S.T., Silva G., Pungartnik C., Brendel M. Study of DNA-emodin interaction by FTIR and UV-Vis spectroscopy. J. Photochem. Photobiol. B: Biol. 2012;111:59–63. doi: 10.1016/j.jphotobiol.2012.03.012. PubMed DOI

Li Y., Luan Y., Qi X., Li M., Gong L., Xue X., Wu X., Wu Y., Chen M., Xing G., et al. Emodin triggers DNA double-strand breaks by stabilizing topoisomerase II-DNA cleavage complexes and by inhibiting ATP hydrolysis of topoisomerase II. Toxicol. Sci. 2010;118:435–443. doi: 10.1093/toxsci/kfq282. PubMed DOI

Fabriciova G., Sanchez-Cortes S., Garcia-Ramos J.V., Miskovsky P. Surface-enhanced Raman spectroscopy study of the interaction of the antitumoral drug emodin with serum albumin. Biopolymers. 2004;74:125–130. doi: 10.1002/bip.20058. PubMed DOI

Bi S.Y., Song D.O., Kan Y.H., Xu D., Tian Y., Zhou X., Zhang H.Q. Spectroscopic characterization of effective components anthraquinones in Chinese medicinal herbs binding with serum albumins. Spectrochim. Acta A: Biomol. Spectrosc. 2005;62:203–212. doi: 10.1016/j.saa.2004.12.049. PubMed DOI

Koistinen K.M., Soininen P., Venalainen T.A., Hayrinen J., Laatikainen R., Perakyla M., Tervahauta A.I., Karenlampi S.O. Birch PR-10c interacts with several biologically important ligands. Phytochemistry. 2005;66:2524–2533. doi: 10.1016/j.phytochem.2005.09.007. PubMed DOI

Sevilla P., Rivas J.M., García-Blanco F., García-Ramos J.V., Sánchez-Cortés S. Identification of the antitumoral drug emodin binding sites in bovine serum albumin by spectroscopic methods. BBA-Proteins Proteom. 2007;1774:1359–1369. doi: 10.1016/j.bbapap.2007.07.022. PubMed DOI

Pecere T., Gazzola M.V., Mucignat C., Parolin C., Dalla V.F., Cavaggioni A., Basso G., Diaspro A., Salvato B., Carli M., et al. Aloe-emodin is a new type of anticancer agent with selective activity against neuroectodermal tumors. Cancer Res. 2000;60:2800–2804. PubMed

Chun-Guan W., Jun-Qing Y., Bei-Zhong L., Dan-Ting J., Chong W., Liang Z., Dan Z., Yan W. Anti-tumor activity of emodin against human chronic myelocytic leukemia K562 cell lines in vitro and in vivo. Eur. J. Pharmacol. 2010;627:33–41. doi: 10.1016/j.ejphar.2009.10.035. PubMed DOI

Kuo T.C., Yang J.S., Lin M.W., Hsu S.C., Lin J.J., Lin H.J., Hsia T.C., Liao L., Yang M.D., Fan M.J., et al. Emodin has cytotoxic and pretoctive effect in rat c6 glioma cells: Roles of Mdr1a and nuclear factor κB in cell survival. J. Pharmacol. Exp. Ther. 2009;330:736–744. doi: 10.1124/jpet.109.153007. PubMed DOI

Ko J.C., Su Y.J., Lin S.T., Jhan J.Y., Ciou S.C., Cheng C.M., Lin Y.W. Suppression of ERCC1 and Rad51 expression through ER1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells. Biochem. Pharmacol. 2010;79:655–664. doi: 10.1016/j.bcp.2009.09.024. PubMed DOI

Chemicalland21 Quinizarin. [(accessed on 7 September 2020)]; Available online: http://www.chemicalland21.com/specialtychem/finechem/QUINIZARIN.htm.

Quinti L., Allen N.S., Edge M., Murphy B.P., Perotti A. A study of the strongly fluorescent species formed by the interaction of the dye 1,4-dihydroxyanthraquinone (quinizarin) with A(III) J. Photochem. Photobiol. A Chem. 2003;155:79–91. doi: 10.1016/S1010-6030(02)00360-X. DOI

Yohida M. Chemistry and hair dyes application of dihydroxy derivates of anthraquinone and naphtoquinone. Prog. Org. Coat. 1997;31:63–72. doi: 10.1016/S0300-9440(97)00019-2. DOI

Brinkworth R.I., Fairle D.P. Hydroxyquinones are competitive nonpeptide inhibitors of HIV-1 proteinase. Biochim. Biophys. Acta. 1995;1253:5–8. doi: 10.1016/0167-4838(95)00183-U. PubMed DOI

Brown J.P. A review of the genetic effects of naturally occurring flavonoids, anthraquinones and related compounds. Mutat. Res. 1980;75:243–277. doi: 10.1016/0165-1110(80)90029-9. PubMed DOI

Longo V., Amato G., Salvetti A., Gervasi P.G. Heterogenous effect of anthraquinones on drug-metabolizing enzymes in the liver and small intestine of rat. Chem. Biol. Interact. 2000;126:63–77. doi: 10.1016/S0009-2797(00)00154-X. PubMed DOI

Carter T.P., Gillispie G.D., Connoll M.A. Intramolecular hydrogen bonding in substituted anthraquinones by laser-induced fluorescence. 1. 1,4-dihydroxyanthraquinone (quinizarin) J. Phys. Chem. 1982;86:192–196. doi: 10.1021/j100391a012. DOI

Smulevich G., Angeloni L., Giovannardi S., Marzocchi M.P. Resonance Raman and polarized light infrared spectra of 1,4-dihydroxyanthraquinone, vibrational studies of the ground and excited electronic states. Chem. Phys. 1982;65:313–322. doi: 10.1016/0301-0104(82)85207-5. DOI

Nigam G., Deppisch B. Redetermination of the structure of 1,4-dihydroxyanthraquinone (C14H8O4) Z. Kristallogr. 1980;151:185–191. doi: 10.1524/zkri.1980.151.3-4.185. DOI

Fabriciová G., Garcia-Ramos J.V., Miškovský P., Sanchez-Cortes S. Absorption and acidic behavior of anthraquinone drugs quinizarin and danthron on Ag nanoparticles studied by Raman spectroscopy. Vib. Spectrosc. 2004;34:273–281. doi: 10.1016/j.vibspec.2004.01.001. DOI

Bondy G.S., Armstrong C.L., Dawson B.A., Héroux-Metcalf C., Neville G.A., Rogers C.G. Toxicity of structurally related anthraquinones and anthrones to mammalian-cell in vitro. Toxicol. In Vitro. 1994;8:329–335. doi: 10.1016/0887-2333(94)90153-8. PubMed DOI

Verebová V., Adamčík J., Danko P., Podhradský D., Miškovský P., Staničová J. Anthraquinones quinizarine and danthron unwind negatively supercoiled DNA and lengthen linear DNA. Biochem. Biophys. Res. Commun. 2014;444:50–55. doi: 10.1016/j.bbrc.2014.01.007. PubMed DOI

IARC . Pharmaceutical Drugs. International Agency for Research on Cancer; Lyon, France: 1990. Dantron (chrysazin; 1,8-dihydroxyanthraquinone) pp. 265–275. PubMed

Mueller S.O., Stopper H., Dekant W. biotransformation of the anthraquinones emodin and chrysophanol by cytochrome P450 enzymes. Bioactivation to genotoxic metabolites. Drug Metab. Dispos. 1998;26:540–546. PubMed

Müller S.O., Eckert I., Lutz W.K., Stopper H. Genotoxicity of the laxative drug components emodin, aloe-emodin and danthron in mammalian cells: Topoisomerase II mediated. Mutat. Res. Genet. Toxicol. 1996;371:165–173. doi: 10.1016/S0165-1218(96)90105-6. PubMed DOI

Downes C.S., Mullinger A.M., Johnson R.T. Inhibitors of DNA topoisomerase II prevent chromatid separation in mammalians cells but do not prevent exit from mitosis. Proc. Natl. Acad. Sci. USA. 1991;88:8895–8899. doi: 10.1073/pnas.88.20.8895. PubMed DOI PMC

Wang J.R., Caron P.R., Kim R.A. The role of DNA topoisomerases in recombination and genomic stability: A double-edged sword. Cell. 1990;62:403–406. doi: 10.1016/0092-8674(90)90002-V. PubMed DOI

Neimeikaité-Čéniené A., Sergediené E., Nivinskas H., Čénas N. Cytotoxicity of natural hydroxyanthraquinones: Role of oxidative stress. Z. Naturforsch. C. 2002;57:822–827. doi: 10.1515/znc-2002-9-1012. PubMed DOI

Lieberman D.F., Fink R.C., Schaefer F.L., Mulcahy R.J., Stark A. Mutagenicity of anthraquinone and hydroxylated anthraquinones in the Ames/Salmonella microsome system. Appl. Environ. Microbiol. 1982;43:1354–1359. doi: 10.1128/AEM.43.6.1354-1359.1982. PubMed DOI PMC

Ferreiro M.L., Rodriguez-Otero J. Ab inition study of the intramolecular proton transfer in dihydroxyanthraquinones. J. Mol. Struct. 2001;542:63–77. doi: 10.1016/S0166-1280(00)00811-3. DOI

Ansari S.S., Khan R.H., Naqvi S. Probing the intermolecular interactions into serum albumin and anthraquinone systems: A spectroscopic and docking approach. J. Biomol. Struct. Dyn. 2018;36:3362–3375. doi: 10.1080/07391102.2017.1388284. PubMed DOI

Jutkova A., Chorvat D., Miskovsky P., Jancura D., Datta S. Encapsulation of anticancer drug curcumin and co-loading with photosensitizer hypericin into lipoproteins investigated by fluorescence resonance energy transfer. Int. J. Pharm. 2019;564:369–378. doi: 10.1016/j.ijpharm.2019.04.062. PubMed DOI

Kozsup M., Dömötör O., Nagy S., Farkas E., Enyedy E.A., Buglyó P. Synthesis, characterization and albumin binding capabilities of quinizarin containing ternary cobalt(III) complexes. J. Inorg. Biochem. 2020;204:110963. doi: 10.1016/j.jinorgbio.2019.110963. PubMed DOI

Crlikova H., Kostrhunova H., Pracharova J., Kozsup M., Nagy S., Buglyó P., Brabec V., Kasparkova J. Antiproliferative, DNA binding, and cleavage properties of dinuclear Co(III) complexes containing the bioactive quinizarin ligand. J. Biol. Inorg. Chem. 2020;25:339–350. doi: 10.1007/s00775-020-01765-4. PubMed DOI

Kočišová E., Chinsky L., Miškovský P. Sequence specific interaction of the photoactive drug hypericin depends on the structural arrangement and the stability of the structure containing its specific 5´AG3´target: A resonance Raman spectroscopy study. J. Biomol. Struct. Dyn. 1999;17:51–59. doi: 10.1080/07391102.1999.10508340. PubMed DOI

Staničová J., Verebová V., Strejčková A. Potential anticancer agent hypericin and its model compound emodin: Interaction with DNA. Čes. Slov. Farm. 2016;65:28–31. PubMed

Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat. Rev. Cancer. 2002;2:48–58. doi: 10.1038/nrc706. PubMed DOI

Aller S.G., Yu J., Ward A., Weng Y., Chittaboina S., Zhou R.P., Harrell P.M., Trinh Y.T., Zhang Q.H., Urbatsch I.L., et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science. 2009;323:1718–1722. doi: 10.1126/science.1168750. PubMed DOI PMC

Regina A., Demeule M., Laplante A., Jodoin J., Dagenais C., Berthelet F., Moghrabi A., Beliveau R. Multidrug resistance in brain tumors: Roles of the blood-brain barrier. Cancer Metastasis Rev. 2001;20:13–25. doi: 10.1023/A:1013104423154. PubMed DOI

Szaflarski W., Sujka-Kordowska P., Januchowski R., Wojtowicz K., Andrzejewska M., Nowicki M., Zabel M. Nuclear localization of P-glycoprotein is responsible for protection of the nucleus from doxorubicin in the resistant LoVo cell line. Biomed. Pharmacother. 2013;67:497–502. doi: 10.1016/j.biopha.2013.03.011. PubMed DOI

Weyergang A., Berstad M.E., Bull-Hansen B., Olsen C.E., Selbo P.K., Berg K. Photochemical activation of drug for the treatment of therapy-resistant cancers. Photochem. Photobiol. Sci. 2015;14:1465–1475. doi: 10.1039/C5PP00029G. PubMed DOI

Nutritional Evaluation of Quinoa Genetic Resources Growing in the Climatic Conditions of Central Europe